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Abstract
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer
(EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high
responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC
includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the
response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 %
of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter
than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is
recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study,
an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC
according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built
a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant
patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival
(p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of
HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and
as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of
personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at
the same time, a promising new therapeutic target in EOC treatment.
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Background
Epithelial ovarian cancer (EOC) represents the 5th leading
cause of cancer-related death worldwide [1] with approxi-
mately 225.500 new diagnoses per year and a mortality
rate greater than 30 % [2]. High-Grade Serous Ovarian
Carcinoma (HGSOC) is the most aggressive histotype,
and accounts for 60–80 % of all ovarian carcinoma [3, 4].
Particularly, HGSOC is characterized by rapid progression
and frequent TP53 mutations [5–7]. Primary treatment
for HGSOC includes surgery and platinum/taxane based
chemotherapy. However, even though 70–80 % of patients
show an initial response to chemotherapy, approximately
25 % relapse within 6 months [8, 9].
According to time to relapse after last chemotherapy
administration, EOC patients are classified into three
platinum-status groups. Patients who experience a recur-
rence after 6 months are deemed platinum-sensitive (PS)
and are good candidates for a platinum rechallenge [10].
Conversely, patients who relapse within 6 months are
classified as platinum-resistant (PR), and are candidate
to alternative treatment schedules that do not include
platinum-derived compounds [11, 12]. Approximately
20 % of all EOC patients belong to this latter group [13].
Lastly, the platinum-refractory group involves patients
who experience disease progression during the course of
treatment. This is the subgroup with the worse progno-
sis and includes less than 10 % of HGSOC patients [14].
The molecular basis of platinum-resistance is not yet
fully understood and experimental results suggest the
involvement of several cellular functions, such as: changes
in cellular uptake and efflux of cisplatin, increased bio-
transformation and detoxification in the liver, loss of
apoptotic signaling after DNA damage has occurred, DNA
repair or DNA damage tolerance. Specifically, genes previ-
ously implicated in EOC pathogenesis such as AURKA1,
ERBB3, CDK2, and mTOR, and novel candidates such as
BRD4, VRK1 and GALK1, have been shown to be involved
in such features, thus becoming potential predictive/prog-
nostic markers in HGSOC [15]. In addition, HDAC4,
STAT1, FORL2 and PIK3R1 were over-expressed in resist-
ant cells when compared to sensitive cells, suggesting their
functional involvement in platinum-resistance [16].
Recently, a meta-analysis indicated Aurora kinase A
(AURKA) as an effective prognosticator in solid tumors
patients, including EOC [17]. Accordingly, a number of
new AURKA inhibitors, such as ZM447439, Hesperadin,
VX-680/MK-0457, AT9283 and AZD1152 are being de-
veloped to target malignant tumors and clinical trials are
ongoing to investigate their efficacy [18].
Aurora kinases are a family of serine/threonine kinases
that play a critical role in the regulation of mitosis, espe-
cially in the distribution of genetic material to daughter
cells [19]. In particular, AURKA has been extensively in-
vestigated for its implication in different neoplasms [20]
and it has been identified as a low penetrance tumor-
susceptibility-gene in human cancer [21]. Moreover, spe-
cific AURKA polymorphisms have been associated with
carcinogenesis [22–28], while its overexpression has been
described in various types of tumors, including laryngeal,
breast, colon, pancreas, ovarian, bladder, liver, and gastric
cancers [29]. This condition may derive from gene ampli-
fication as well as deregulation of gene expression; in
addition, inhibition of protein degradation was also re-
ported [20, 30]. The molecular mechanism by which
AURKA contributes to tumorigenesis is complex, often
implying apoptosis and/or autophagy signaling perturb-
ation. Indeed, AURKA interacts with many tumor sup-
pressor proteins (p53, BRCA1, glycogen synthase kinase
(GSK)-3b, and c-Myc), thus accounting for significant
alteration of their modulatory functions [31–34]. Further-
more, AURKA overexpression seems to occur as an early
event in EOC development [35, 36].
On these bases, we investigated the association between
the expression of AURKA in HGSOC patients’ specimens
and clinical outcome, taking into account both response
to chemotherapy and survival.
Methods
Forty-one patients with confirmed diagnosis of HGSOC
(mean age: 63.43 years; range: 44–88 years) consecutively
treated in our institution between 2009 and 2015, were
enrolled in this study. Eligibility criteria included histo-
logical diagnosis of EOC, age > 18 years old, at least one
previous line of treatment including a platinum-based
schedule. Patients were grouped as PR (platinum-resist-
ant) and PS (platinum-sensitive) taking into account the
classification-system based on the “platinum-free interval”,
i.e. the time-frame between the end of chemotherapy
treatment and recurrence, as previously described.
Surgical specimens were retrieved from the archive files
of the Department of Health Sciences, Surgical Pathology
Section of the University Magna Græcia of Catanzaro,
Italy. Clinical data have been retrieved from medical
records of the Gynecologic and Medical Oncology Units
of the same Institution. All data were entered into an elec-
tronic database.
A detailed clinical follow-up, ranging from 3 to
50 months after surgery (average value: 19.13 months)
was available for all patients. Written informed consent
was obtained from each patient being studied and all pro-
cedures performed in this study were performed for diag-
nostic purposes, in accordance with the ethical standards
of the institutional committee responsible for human
experimentation.
Immunohistochemical staining procedures were car-
ried out on formalin-fixed, paraffin-embedded archival
cell blocks. For AURKA identification, a three layer
biotin-avidin-peroxidase system was utilized. Briefly,
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xylene dewaxed and alcohol-rehydrated serial tissue sec-
tions (4 μm-thick) were treated in EDTA buffer at 98 C°
for 50 min, according to the antigen retrieval method.
Afterwards, endogenous peroxidase activity was blocked
with 3 % hydrogen peroxide solution. For the evaluation
of AURKA signal, mouse monoclonal anti-Aurora Kinase
2 (clone JLM28, 1:50 dilution; Leica Biosystems, United
Kingdom) was applied for 1 h at RT. Biotinylated second-
ary antibody and avidin-biotin peroxidase complex were
then applied and allowed to react for 30 min at RT.
AURKA signals were visualized after addition of 0.01 %
DAB (3, 3’-diaminobenzidine tetrahydrochloride). Nuclear
counterstaining was perfomed with hematoxylin.
A semi-quantitative analysis was performed, evaluating
both percentage of AURKA-positive cells and staining in-
tensity (intensity and percentage-based approaches), using
the score system by Allred et al. [37–39]. A percentage-
based approach was used in order to estimate the propor-
tion of positively stained tumor cells (0: none, 1:<1 %, 2:
1–10 %, 3: 10–33 % 4: 33–66 %, 5: 66–100 %) Fig. 1 (a-f).
Average estimated intensity of staining in positive cells
was assigned as an intensity score (0 = none; 1 = weak; 2 =
intermediate; 3 = strong) Fig. 2 (a-c).
An immunoreactive score ranging from 0 to 8 was de-
fined as the sum of percentage score and intensity score.
Negative control sections for immunohistochemistry were
processed without primary antibody.
Two investigators performed clinical data collection
and statistical analyses independently.
Primary endpoint was response rate (RR) according to
platinum response. Secondary endpoint was overall sur-
vival (OS) in all patients. A Student's test was used to com-
pare the scores of the two patient groups. Kaplan Meier
curves and Log Rank test were used to describe and evalu-
ate the effect of several variables on outcome. All tests
were considered statistically significant when the p-value
was <0.05. The relative hazard ratios (HR) with 95 % confi-
dence intervals (95 % CIs) were calculated using SPSS
(version 19) statistical package and Graphpad PRISMA
(version 6.0).
Results
Clinical and pathological parameters of patients and im-
munohistochemical findings are detailed in Table 1. To
verify the reliability of the sample, we evaluated if patients
with a platinum-sensitive disease experienced the longest
survival. As reported in Additional file 1: Figure S1, ac-
cording to published literature, patients in the PS group
presented the best outcome (50 versus 14 months, p <
0.0001) thus confirming the reliability of the sample. Sub-
sequently, we confirmed the original diagnosis of HGSOC
for all cases examined. Two cases were stage IIA, 1 case
stage IIB, 4 cases stage IIC, 1 case stage IIIA, 7 cases stage
IIIB, 16 cases stage IIIC and 10 cases stage IV tumours
according to AJCC guidelines.
The expression of AURKA in neoplastic cells, using
the specific score system, was comprised between 0 and
Fig. 1 Immunohistochemical analysis of AURKA in surgical specimens of HGSOC (percentage-based approach). The panel shows a proportion
score assigned on the basis of the percentage of AURKA positive tumor cells. 0: no AURKA-positive cells (a), 1:<1 % (b), 2: 1–10 % (c), 3: 10–33 %
(d) 4: 33–66 % (e), 5: 66–100 % (f). Magnification 100x (a), 200x (b-f)
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8. Figure 3 shows the average score value described for
each group of patients.
As shown in Fig. 3a, both AURKA intensity score and
AURKA+ cells score were highly associated with platinum-
response. However, the AURKA total score demonstrated
the highest capability to discriminate patients belonging to
the two different platinum-sensitivity conditions (p < 0.001).
Furthermore, high levels of AURKA were also correlated
to a worse overall survival (p = 0.001; HR 0.14) (Fig. 4).
Discussion
At present, platinum-based regimens represent the best
therapeutic option for EOC patients. Taking into account
that platinum-response is one of the most important
prognostic factors for these patients, the identification of
predictive biomarkers may be crucial in clinical practice.
In our study, we observed a statistically significant
correlation between high level of AURKA in HGSOC
specimens and platinum-resistance. Our results are in
Fig. 2 Immunohistochemical analysis of AURKA in surgical specimens of HGSOC (intensity-based approach). The panel shows three examples of
different intensity score value. 1 = weak (a); 2 = intermediate (b); 3 = strong (c) Magnification 400x (a), 200x (b, c)
Table 1 Distribution of AURKA in HGSOC patients. The average score value of AURKA is low in platinum sensitive patients and high
in platinum resistant patients ***(p < 0.001)
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line with in vitro studies, demonstrating that overexpres-
sion of AURKA accounts for resistance to taxane and plat-
inum agents [17, 18, 40, 41]. Additionally, recent reports
show that cells depleted of AURKA are more sensitive to
cisplatin-induced apoptosis, and elevated expression of
Aurora kinase A antagonizes this response [42].
From a practical point of view, our series may be strati-
fied into three different groups according to the score
obtained and the platinum-status. All the patients with
scores 6–8 were platinum-resistant, while those with
scores 0–2 were all platinum-sensitive. Therefore, we have
determined two cut-off (score 2 and score 6) that seem to
Fig. 3 Correlation of AURKA scores with platinum-response. A strong association between both Intensity (Panel a) and Cell percentage (Panel b)
scores with platinum response is showed. Panel c reports the correlation between AURKA total score and platinum response
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be able to identify the patients responsiveness to platinum
treatment from chemoresistant patients. Patients with
intermediate score, between three and six presented con-
trasting outcomes. For these patients, a FISH-based ap-
proach or further molecular analyses should be
recommended in order to deeply characterize and quantify
the expression of AURKA and subsequently correlate it
with outcome measures.
Taking into account the poor prognosis of platinum-
resistant patients, the routine use of this new biomarker
could help clinicians in choosing the best frontline treat-
ment. Indeed, by evaluating the AURKA pattern, che-
moresistant patients in advanced stages could be easily
identified, in order to prevent unnecessary severe side
effects as well as to reduce treatment costs [41].
To the best of our knowledge, the expression and prog-
nostic significance of AURKA in HGSOC has been poorly
investigated. In 2007, Lessmann et al. suggested AURKA
as a predictive marker in EOC. However, no data have
been yet reported on its potential role in the prediction of
response to platinum/taxane treatment [43].
The major limitations of our study is the low number
of patients enrolled, the retrospective design and the
lack of an independent validation series. Indeed, our
work should be considered “hypothesis generating” and
further prospective validation is eagerly awaited and is
planned in the next future.
Conclusion
The reported findings suggest AURKA as a new tool to
predict the clinical behavior of HGSOC. Particularly, these
results suggest that AURKA may have a role both as pre-
dictor of platinum-resistance and prognostic factor. In-
deed, in the era of personalized medicine, the availability
of new predictive biomarkers is crucial for the selection of
better treatment in the scenario of a continuum of care.
Moreover our findings suggest that targeting AURKA may
hold promise as a new therapeutic strategy in EOC
management.
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